Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
04/2003
04/10/2003WO2003028735A1 Estrogen/gestagen combination preparation and application thereof
04/10/2003WO2003028624A2 Levothyroxine compositions and methods
04/10/2003WO2003002103A3 Hydrophobic dopamine agonists administered to the dermis
04/10/2003WO2003002092A3 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
04/10/2003WO2002102978A3 Human growth hormone antagonists
04/10/2003WO2002102394A3 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
04/10/2003WO2002094203A3 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
04/10/2003WO2002092064A3 Therapeutic method for inducing tolerance
04/10/2003WO2002071827A3 Retinoid x receptor modulators
04/10/2003WO2002055688A3 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
04/10/2003WO2002049629A3 Methods for reducing chronic stress in mammals
04/10/2003WO2002043767A8 Improved oral delivery of peptides using enzyme-cleavable membrane translocators
04/10/2003WO2002008396A3 Human proteases
04/10/2003US20030069434 Antiestrogenic properties or tissue-selective estrogenic properties
04/10/2003US20030069308 Antidiabetic agents
04/10/2003US20030069303 Osteoporosis, postmenopause
04/10/2003US20030069287 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
04/10/2003US20030069216 Interconversion of inactive 11- keto steroids with their active 11B-hydroxy equivalents, especially between cortisone and cortisol; administering a 11-beta-reductase inhibitor such as carbenoxolone
04/10/2003US20030069181 Alternative splice forms of proteins as basis for multiple therapeutic modalities
04/10/2003US20030068664 Monitoring effectiveness of preferential cancer immunotherapy; obtain mammal, administer immunotherapy, evaluate effectiveness of treatment
04/10/2003US20030068279 Dispersible pharmaceutical-based dry powder composition comprising a therapeutically effective amount of pharmaceutical in combination with a pharmaceutically acceptable carrier
04/10/2003US20030068278 Administering fine powder of active material; measured aerosol
04/10/2003US20030066524 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage
04/10/2003CA2462795A1 Secreted proteins
04/10/2003CA2462075A1 Estrogen/gestagen combination preparation and application thereof
04/10/2003CA2459825A1 Compounds useful as reversible inhibitors of cysteine proteases
04/09/2003EP1300398A1 Propane-1,3-dione derivatives
04/09/2003EP1299545A2 Drug metabolizing enzymes
04/09/2003EP1299538A2 Secreted proteins
04/09/2003EP1299412A2 Protein modification and maintenance molecules
04/09/2003EP1299385A2 Fused cyclic modulators of nuclear hormone receptor function
04/09/2003EP1299374A1 Novel non-psychotropic cannabinoids
04/09/2003EP1299362A1 Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof
04/09/2003EP1299157A1 Composition and applicator for topical substance delivery
04/09/2003EP1299094A2 Selective androgen receptor modulators and methods for their identification, design and use
04/09/2003EP1299092A2 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel
04/09/2003EP1299010A1 Vitamin k and essential fatty acids
04/09/2003EP1037587B1 Site-specific preparation of polyethylene glycol-grf conjugates
04/09/2003CN1409726A Type I cytokine receptor TCCR
04/09/2003CN1409703A 4-aminopiperidine derivatives and their use as medicine
04/09/2003CN1409701A Crystalline form of (S)-2-ethoxy-3-[4-(2-{4-methane sulfonyloxy phenyl} ethoxy) phenyl] propanoic acid
04/09/2003CN1409640A Polypeptide composition with improved stability
04/09/2003CN1409639A TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
04/09/2003CN1409635A Treatment of systemic lupus erythematosus with dehydroepiandrosterone
04/08/2003US6545049 E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof
04/08/2003US6545018 Oxamic acids and derivatives as thyroid receptor ligands
04/08/2003US6544999 Use as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent, and especially used for the treatment of insomnia.
04/08/2003US6544995 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein
04/08/2003US6544981 Anticoagulants, cardiovascular disorders
04/08/2003CA2084431C 17-spirofuran-3'-ylidene steroids
04/08/2003CA2074322C A composition for the sustained and controlled release of medicamentous substances and a process for preparing the same
04/08/2003CA2048243C 4-amino- 4,6-steroids and their use as 5-.alpha.-reductase inhibitors
04/03/2003WO2003027263A2 Proteins associated with cell growth, differentiation, and death
04/03/2003WO2003027228A2 Receptors and membrane-associated proteins
04/03/2003WO2003027113A1 1,6-naphthyridine derivatives as antidiabetics
04/03/2003WO2003027112A1 1, 8-naphthyridine derivatives as antidiabetics
04/03/2003WO2003027107A1 Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
04/03/2003WO2003027105A1 Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors
04/03/2003WO2003027101A1 Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors
04/03/2003WO2003027100A1 Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
04/03/2003WO2003027096A1 Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
04/03/2003WO2003027095A1 Substituted 3-pyridyl tetrazoles as steroid c17,20 lyase inhibitors
04/03/2003WO2003027094A2 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
04/03/2003WO2003027090A2 Bicyclic heterocycles as rxr ligands
04/03/2003WO2003027085A2 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
04/03/2003WO2003027081A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER
04/03/2003WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
04/03/2003WO2003027065A1 3-desoxy-vitamin d3 analog esters
04/03/2003WO2003026673A1 Modulation of vitamin storage
04/03/2003WO2003026649A1 Methods of increasing endogenous testosterone levels
04/03/2003WO2003026635A2 Improved method of treating the syndrome of type 2 diabetes in humans
04/03/2003WO2003026579A2 Combination therapies for immune mediated diseases
04/03/2003WO2003026568A2 Androstanes as androgen receptor modulators
04/03/2003WO2002102799A3 Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists
04/03/2003WO2002102313A3 Pyrimidine inhibitors of phosphodiesterase (pde) 7
04/03/2003WO2002092016A3 Therapeutic use of rank antagonists
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002066649A3 ANTI-INTERFERON-α ANTIBODIES
04/03/2003US20030065023 Anticancer agents, viricides, psychological disorders
04/03/2003US20030065017 Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists / antagonists, estrogens and progestins
04/03/2003US20030065012 Estrogen receptor modulators
04/03/2003US20030065008 Hormone replacement therapy; side effect reduction
04/03/2003US20030065004 Androgen receptor modulators and methods for use thereof
04/03/2003US20030064973 Sexual disorders
04/03/2003US20030064430 Novel steroid-activated nuclear receptors and uses therefor
04/03/2003US20030064410 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids
04/03/2003US20030064097 For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents
04/03/2003US20030064052 Useful for maintaining controlled and reliable dosage of the therapeutic agent via pulmonary delivery
04/03/2003US20030064036 Coating and binding agent for pharmaceutical formulations with improved storage stability
04/03/2003CA2463039A1 1,6-naphthyridine derivatives as antidiabetics
04/03/2003CA2461666A1 Combination therapies for immune mediated diseases
04/03/2003CA2461363A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
04/03/2003CA2461360A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
04/03/2003CA2461132A1 1, 8-naphthyridine derivatives as antidiabetics
04/03/2003CA2460953A1 Proteins associated with cell growth, differentiation, and death
04/03/2003CA2460541A1 Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer
04/03/2003CA2459943A1 Androstanes as androgen receptor modulators
04/03/2003CA2459789A1 3-desoxy-vitamin d3 analog esters
04/03/2003CA2458661A1 Methods of increasing endogenous testosterone levels
04/03/2003CA2458279A1 Modulation of vitamin storage
1 ... 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 ... 290